Accelrys Adds Another Scientific Software Company to Its Portfolio

-
Courtesy Xconomy
After merging with Symyx Technologies in 2010, acquiring Contur Sofware in 2011, and buying VelQuest earlier this year, San Diego scientific software developer Accelrys says today it is buying Aegis Analytical.
Accelrys is paying $30 million in cash for Aegis, a company based in Lafayette, CO, (near Boulder) that makes software used to monitor biotech product development and manufacturing processes. In a statement today, Accelrys says the deal helps to further expand its suite of software used to manage the life cycle of innovation among pharmaceutical companies and in other industries.
Aegis has about 40 full-time and contract employees, and “the idea is to keep the business in Boulder and fairly intact,” Accelrys CFO Michael Piraino told me during a phone interview earlier this afternoon. Aegis CEO Robert Di Scipio will stay with the merged company through the transition to new ownership.
About two-thirds of Accelrys’ customers are pharmaceutical and biotech companies, according to Piraino. The company also provides its software-as-a-service to customers specializing in oil & gas development, cleantech, food and beverage, and other industries.
The company’s statement quotes Accelrys CEO Max Carnecchia as saying, “The industries we serve are undergoing significant changes, requiring them to move from a status quo approach to one that breaks down the barriers to operational excellence, innovation productivity and global competitiveness.”
Accelrys says companies that operate in regulated environments are finding it difficult to manage complex manufacturing in real-time because they’re relying on paper notebooks and other outmoded tools to monitor R&D, quality assurance, and other industrial processes.
Accelrys says addressing such problems requires a global and holistic approach that enables businesses to predict, prevent, and solve problems throughout product development, quality control, and manufacturing process. Accelrys says that without the kind of cloud-based software it provides, companies risk compromising the quality of their products, falling out of regulatory compliance, slowing operations and increasing commercialization costs. Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at bbigelow@xconomy.com

Comments

Post a Comment

Popular posts from this blog

Sequence Analysis is still sexy:Dual Descriptor Method for Biological Sequence Analysis

-
The emergence of “Systems Biology” in recent years highlights the systematic viewpoint of bio-system modeling. Building on such a background, Dual Descriptor Method, a generic methodology for biological sequence analysis is proposed. From a systematic perspective, Dual Descriptor is defined as a two element set of Composition Weight Map and Position Weight Function which aim at reflecting the composition and permutation information of a sequence. An alternate training algorithm is provided to get an optimum description of the building patterns of the sequences. In this paper , dual descriptor method has been applied to the analysis of two typical problems of molecular biology: gene identification and the prediction of protein function. Satisfactory and insightful results are achieved. Owing to the generality of this methodology, dual descriptor method has wide application perspective for many problems of pattern recognition, especially those involved in “Systems Biology”. Be a part of
Read more

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

-
Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. &quo
Read more

List of Cheminformatics Companies & Institutions

-
Accelrys ACD/Labs (Advanced Chemistry Development, Inc.) Afferent Systems Inc. Agilent Technologies Aureus Pharma Barnard Chemical Information Ltd. (John Barnard and Geoff Downs) SEE: digital chemistry Bio-Rad Laboratories BioReason BioSolveIT BlueObelisk.org Bruker Daltonics Inc. Cambridge Crystallographic Data Centre CambridgeSoft Corporation CARB Center for Advanced Research in Biotechnology (NIST/University of Maryland) Cengent Therapeutics (Genes to Leads). Acquired by Inncardio, Inc. Center for Molecular Modeling (NIH) Centre for Molecular and Biomolecular Informatics CMBI (formerly: CAOS/CAMM: Dutch National Center for Computer-Assisted Chemistry and Molecular Modelling) Cerep ChemAxon ChemDiv, Inc. (Chemical Diversity) Chemical Abstracts Service Chemical Computing Group, Inc. Chemical Simulations Group ChemInnovation Software ChemNavigator ChemSW (Chemistry Software for Windows, formerly: WindowChem) Chenomx Inc. CIS Chemical Information System CombiChem.net CompuChem C
Read more